Breaking News Instant updates and real-time market news.

2023-03-29 08:49:15 IONS Ionis Pharmaceuticals $34.30 / +0.575 (+1.71%) , BIIB Biogen $270.29 / +0.66 (+0.24%) 08:49 03/29/23 03/29 08:49 03/29/23 08:49	Ionis Pharmaceuticals' IONIS-MAPTRx shows tau reduction efficacy in Alzheimer's Ionis Pharmaceuticals (IONS) reported that its partner Biogen (BIIB) presented new Phase 1b clinical data showing that IONIS-MAPTRx reduced soluble tau protein in cerebrospinal fluid in a dose-dependent and sustained manner in patients with early-stage Alzheimer's disease. IONIS-MAPTRx also reduced aggregated tau pathology in all brain composites assessed. The primary endpoint of the Phase 1b study and long-term extension study was safety and tolerability, with biomarker data as an exploratory endpoint. The accumulation of pathological tau tangles has been shown to promote neuronal damage and death. IONIS-MAPTRx is an investigational antisense medicine discovered by Ionis that is being developed by Biogen. It is designed to target microtubule-associated protein tau mRNA and prevent production of tau protein. In this study, the majority of adverse events were mild or moderate in severity, of which the most common were headache, back pain, and post-lumbar puncture syndrome. The results showed that IONIS-MAPTRx reduced biomarkers of soluble tau in CSF in a dose-dependent and sustained manner, with all dose groups showing approximately a 60% reduction from baseline CSF tau levels by the end of the LTE. The Phase 2 study of IONIS-MAPTRx is in progress and currently recruiting participants in the U.S. IONS Ionis Pharmaceuticals $34.30 / +0.575 (+1.71%) BIIB Biogen $270.29 / +0.66 (+0.24%)	04 May 06 Jul 05 Aug 22 Dec

2023-03-29 08:49:15

IONS

Ionis Pharmaceuticals

$34.30 / +0.575 (+1.71%)

, BIIB

Biogen

$270.29 / +0.66 (+0.24%)

08:49

03/29/23

03/29

08:49

03/29/23

08:49

Ionis Pharmaceuticals' IONIS-MAPTRx shows tau reduction efficacy in Alzheimer's

Ionis Pharmaceuticals (IONS) reported that its partner Biogen (BIIB) presented new Phase 1b clinical data showing that IONIS-MAPTRx reduced soluble tau protein in cerebrospinal fluid in a dose-dependent and sustained manner in patients with early-stage Alzheimer's disease. IONIS-MAPTRx also reduced aggregated tau pathology in all brain composites assessed. The primary endpoint of the Phase 1b study and long-term extension study was safety and tolerability, with biomarker data as an exploratory endpoint. The accumulation of pathological tau tangles has been shown to promote neuronal damage and death. IONIS-MAPTRx is an investigational antisense medicine discovered by Ionis that is being developed by Biogen. It is designed to target microtubule-associated protein tau mRNA and prevent production of tau protein. In this study, the majority of adverse events were mild or moderate in severity, of which the most common were headache, back pain, and post-lumbar puncture syndrome. The results showed that IONIS-MAPTRx reduced biomarkers of soluble tau in CSF in a dose-dependent and sustained manner, with all dose groups showing approximately a 60% reduction from baseline CSF tau levels by the end of the LTE. The Phase 2 study of IONIS-MAPTRx is in progress and currently recruiting participants in the U.S.

IONS

Ionis Pharmaceuticals

$34.30 / +0.575 (+1.71%)

BIIB

Biogen

$270.29 / +0.66 (+0.24%)

04
May
06
Jul
05
Aug
22
Dec

OTHER BREAKING NEWS FROM THE FLY

Recommendations	Hims & Hers price target lowered to $11 from $12 at Piper Sandler » 07:15 05/30/23 05/30 07:15 05/30/23 07:15 HIMS Hims & Hers $9.07 / +0.03 (+0.33%) Piper Sandler lowered the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:15 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options HIMS Hims & Hers $9.07 / +0.03 (+0.33%) 05/08/23 Hims & Hers up 6% after Q1 earnings, FY23 guidance raise 05/08/23 Hims & Hers reports end-Q1 subscribers up 87% to 1.2M 02/28/23 Hims & Hers rises 20.7% 02/28/23 Hims & Hers rises 11.3% HIMS Hims & Hers $9.07 / +0.03 (+0.33%) 05/09/23 SVB Securities SVB Securities keeps Market Perform on Hims & Hers, raises price target to $11 05/09/23 BofA Hims & Hers price target raised to $15 from $13.50 at BofA 05/09/23 Piper Sandler Hims & Hers price target raised to $12 from $11 at Piper Sandler 05/09/23 Citi Citi 'unbothered' by issues driving volatility in Hims & Hers shares HIMS Hims & Hers $9.07 / +0.03 (+0.33%) 05/08/23 Hims & Hers sees Q2 revenue $200M-$205M, consensus $183.3M 05/08/23 Hims & Hers raises FY23 revenue view to $810M-$830M, consensus $755.28M 05/08/23 Hims & Hers reports Q1 EPS (5c), consensus (7c) 02/27/23 Hims & Hers sees FY23 revenue $735M-$755M, consensus $726.92M HIMS Hims & Hers $9.07 / +0.03 (+0.33%) 02/28/23 What You Missed On Wall Street On Tuesday 02/28/23 What You Missed On Wall Street This Morning 02/28/23 Fly Intel: Pre-market Movers 02/27/23 Fly Intel: After-Hours Movers 06/01/23 Hims & Hers Health, Inc. HIMS Hims & Hers $9.07 / +0.03 (+0.33%) 05/08/23 Hims and Hers Health options imply 13.3% move in share price post-earnings 03/16/23 Hims and Hers Health call volume above normal and directionally bullish 03/07/23 Hims and Hers Health call volume above normal and directionally bullish 02/27/23 Hims and Hers Health options imply 13.1% move in share price post-earnings
Hot Stocks	Clover Leaf Capital announces option agreement between North Shore, Skyharbour » 07:15 05/30/23 05/30 07:15 05/30/23 07:15 CLOE Clover Leaf Capital $11.26 / +0.06 (+0.54%) Clover Leaf Capital… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:15 Get Free Trial ShowHide Related Items >><< Company News CLOE Clover Leaf Capital $11.26 / +0.06 (+0.54%) 12/23/22 Clover Leaf Capital announces definitive agreement for qualifying transaction
Hot Stocks	Protalix CEO issues letter to shareholders » 07:15 05/30/23 05/30 07:15 05/30/23 07:15 PLX Protalix $2.06 / -0.035 (-1.67%) Protalix announced the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:15 Get Free Trial ShowHide Related Items >><< Company News On The Fly Events Options PLX Protalix $2.06 / -0.035 (-1.67%) 05/23/23 Protalix to join Russell 3000 Index 05/18/23 Protalix to receive $20M milestone payment from Chiesi Global Rare Disease 05/10/23 Chiesi, Protalix announce FDA approval for Elfabrio 03/21/23 Protalix doses first patient in PRX-115 trial PLX Protalix $2.06 / -0.035 (-1.67%) 04/14/23 Biotech Alert: Searches spiking for these stocks today 12/07/22 Biotech Alert: Searches spiking for these stocks today 06/28/23 Protalix BioTherapeutics, Inc. PLX Protalix $2.06 / -0.035 (-1.67%) 05/23/23 Largest borrow rate increases among liquid names 05/17/23 Largest borrow rate increases among liquid names 04/05/23 Largest borrow rate increases among liquid names
General news	FX Action: » 07:15 05/30/23 05/30 07:15 05/30/23 07:15 $ECON Economic Data / + FX Action: the DXY dollar… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:15 Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly Technical Analysis $ECON Economic Data / + 03/22/23 Senators Scott, Warren unveil bipartisan Fed oversight legislation 03/01/23 Einhorn says investors should be 'bearish on stocks and bullish on inflation' $ECON Economic Data / + $ECON Economic Data / + 05/25/23 Biden, McCarthy edging close to debt ceiling deal, Reuters reports 03/29/23 Powell did not 'predict' another rate hike in meeting, CNBC reports 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says $ECON Economic Data / + 05/24/23 What You Missed On Wall Street On Wednesday 05/03/23 What You Missed On Wall Street On Wednesday 04/19/23 What You Missed On Wall Street On Wednesday 03/22/23 What You Missed On Wall Street On Wednesday $ECON Economic Data / + 03/22/23 Fed says 'additional policy firming may be appropriate'
Recommendations	Natera price target lowered to $70 from $80 at Piper Sandler » 07:14 05/30/23 05/30 07:14 05/30/23 07:14 NTRA Natera $48.66 / +0.42 (+0.87%) Piper Sandler analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:14 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events NTRA Natera $48.66 / +0.42 (+0.87%) 05/15/23 Invitae to appeal jury's veredict in Natera patent case 05/15/23 Jury rules in favor of Natera in patent suit against ArcherDX/Invitae 05/15/23 Jury rules in favor of Natera in patent suit against ArcherDX/Invitae 03/22/23 Natera announces new study on its personalized, tumor-informed MRD test NTRA Natera $48.66 / +0.42 (+0.87%) 05/10/23 Baird Natera price target raised to $66 from $65 at Baird 05/10/23 Credit Suisse Natera price target raised to $70 from $65 at Credit Suisse 05/05/23 UBS Natera initiated with a Buy at UBS 03/30/23 Piper Sandler Piper says inclusion of Natera's Signatera in NCCN guidelines 'matter of time' NTRA Natera $48.66 / +0.42 (+0.87%) 05/09/23 Natera raises FY23 revenue view to $995M-$1.015B, consensus $990.7M 05/09/23 Natera reports Q1 EPS ($1.23), consensus ($1.15) 02/28/23 Natera sees FY23 revenue $980M-$1.0B, consensus $988.88M 02/28/23 Natera reports Q4 EPS ($1.37), consensus ($1.42) 16 Nov NTRA Natera $48.66 / +0.42 (+0.87%) 12/16/22 What You Missed On Wall Street On Friday 05/31/23 20th Annual Institutional Investor Conference 06/02/23 2023 ASCO Annual Meeting 06/09/23 Natera, Inc.
Hot Stocks	NeoGenomics to showcase RaDaR Assay at ASCO meeting » 07:12 05/30/23 05/30 07:12 05/30/23 07:12 NEO NeoGenomics $17.27 / -0.12 (-0.69%) NeoGenomics announced new… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:12 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly NEO NeoGenomics $17.27 / -0.12 (-0.69%) 04/04/23 NeoGenomics provides five-year financial projection 03/22/23 NeoGenomics, Massive Bio collaborate to accelerate oncology drug discovery 03/16/23 NeoGenomics announces commercial availability of RaDaR assay 03/13/23 NeoGenomics announces launch of Neo Comprehensive CGPs NEO NeoGenomics $17.27 / -0.12 (-0.69%) 05/16/23 Raymond James NeoGenomics downgraded to Market Perform from Outperform at Raymond James 05/16/23 Raymond James NeoGenomics downgraded to Market Perform from Outperform at Raymond James 05/15/23 Piper Sandler NeoGenomics price target raised to $23 from $20 at Piper Sandler 05/09/23 TD Cowen NeoGenomics price target raised to $22 from $20 at TD Cowen NEO NeoGenomics $17.27 / -0.12 (-0.69%) 04/04/23 NeoGenomics sees FY23 revenue $545M-$555M, consensus $549.97M 02/23/23 NeoGenomics sees 2023 revenue $545M-$555M, consensus $545.08M 02/23/23 NeoGenomics reports Q4 adjusted EPS (6c), consensus (16c) NEO NeoGenomics $17.27 / -0.12 (-0.69%) 05/16/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/09/23 What You Missed On Wall Street On Tuesday 05/09/23 What You Missed On Wall Street This Morning 05/09/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
Hot Stocks	Contango Ore to join Russell 3000 index » 07:12 05/30/23 05/30 07:12 05/30/23 07:12 CTGO Contango Ore $25.31 / -0.79 (-3.03%) Contango Ore announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:12 Get Free Trial ShowHide Related Items >><< Street Research CTGO Contango Ore $25.31 / -0.79 (-3.03%) 10/31/22 Roth Capital Contango Ore initiated with a Buy at Roth Capital
Hot Stocks	BeiGene: BRUKINSA approved by Health Canada for CLL treatment in adults » 07:11 05/30/23 05/30 07:11 05/30/23 07:11 BGNE BeiGene $236.64 / +8.45 (+3.70%) BeiGene announced that… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:11 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events BGNE BeiGene $236.64 / +8.45 (+3.70%) 05/17/23 BeiGene,The Max Foundation team to bring Brukinsa to countries in need 05/07/23 BeiGene receives new approvals for BRUKINSA in China 04/17/23 MapKure, SpringWorks, BeiGene present data from Phase 1a/1b study of BGB-3245 04/13/23 BeiGene opens office in Sao Paulo BGNE BeiGene $236.64 / +8.45 (+3.70%) 04/12/23 BofA BeiGene price target raised to $263.30 from $230.10 at BofA 03/17/23 Piper Sandler Leap Therapeutics news 'disappointing at first glance,' says Piper Sandler 03/17/23 Mizuho Leap Therapeutics price target lowered to $2 from $3 at Mizuho 02/28/23 Cowen BeiGene price target raised to $262 from $213 at Cowen BGNE BeiGene $236.64 / +8.45 (+3.70%) 05/04/23 BeiGene reports Q1 EPS ($3.34), consensus ($3.77) 02/27/23 BeiGene reports Q4 EPS ($4.29), consensus ($5.40) BGNE BeiGene $236.64 / +8.45 (+3.70%) 04/14/23 FDA resuming China lab inspections could benefit Amicus, BeiGene, Barron's says BGNE BeiGene $236.64 / +8.45 (+3.70%) 02/27/23 Fly Intel: Pre-market Movers 01/03/23 Fly Insider: Terns Pharma, Best Buy among week's notable insider trades 00:00 Today 4th Annual Oncology Innovation Summit: Insights for ASCO & EHA 06/02/23 2023 ASCO Annual Meeting
Hot Stocks	PyroGenesis signs contract for five metric tons of titanium metal powder » 07:11 05/30/23 05/30 07:11 05/30/23 07:11 PYR PyroGenesis / + PyroGenesis Canada… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:11 Get Free Trial ShowHide Related Items >><< Company News Earnings PYR PyroGenesis / + 05/23/23 PyroGenesis receives non-compliance letter from Nasdaq 05/19/23 PyroGenesis CEO files updated early warning report 05/18/23 PyroGenesis announces receipt of $2M payment under existing Drosrite contract 05/03/23 PyroGenesis' Pyro Green-Gas completes integrated cold test for client PYR PyroGenesis / + 03/31/23 PyroGenesis reports Q4 revenue $3.3M vs $7.2M last year
Hot Stocks	Asante Gold provides update on management cease trade order » 07:11 05/30/23 05/30 07:11 05/30/23 07:11 ASGOF Asante Gold $1.49 / + (+0.00%) Asante Gold provided its… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:11 Get Free Trial ShowHide Related Items >><< Company News Street Research ASGOF Asante Gold $1.49 / + (+0.00%) 05/24/23 Asante Gold provides update on discussions with Fujairah 05/16/23 Asante Gold provides update on management cease trade order 05/15/23 Asante Gold reports higher mineral resources in amended Chirano mine report 05/08/23 Asante Gold grants exclusivity period to Fujairah Holding ASGOF Asante Gold $1.49 / + (+0.00%) 05/09/23 Canaccord Asante Gold downgraded to Hold from Speculative Buy at Canaccord 04/21/23 Canaccord Asante Gold price target lowered to C$2.20 from C$3 at Canaccord

Initiation	William Blair starts Vertex with Outperform, $382 fair value estimate » 07:10 05/30/23 05/30 07:10 05/30/23 07:10 VRTX Vertex Pharmaceuticals $329.89 / -2.63 (-0.79%) William Blair analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:10 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options VRTX Vertex Pharmaceuticals $329.89 / -2.63 (-0.79%) 05/03/23 Vertex announces FDA approval for KALYDECO to treat eligible infants with CF 04/26/23 Vertex announces U.S. FDA approval for expanded use of Trikafta 04/25/23 Stablix, Vertex collaborate for targeted protein stabilization therapeutics 04/10/23 Sana Biotechnology CMO Sunil Agarwal to leave, Gary Meininger to succeed VRTX Vertex Pharmaceuticals $329.89 / -2.63 (-0.79%) 05:51 Today William Blair Vertex Pharmaceuticals initiated with an Outperform at William Blair 05/25/23 WestPark Capital Vertex Pharmaceuticals initiated with a Hold at WestPark Capital 05/04/23 Piper Sandler Vertex Pharmaceuticals assumed with an Overweight at Piper Sandler 05/03/23 Maxim Vertex Pharmaceuticals price target raised to $400 from $325 at Maxim VRTX Vertex Pharmaceuticals $329.89 / -2.63 (-0.79%) 05/01/23 Vertex Pharmaceuticals backs FY23 revenue view of $9.55B-$9.7B, consensus $9.71B 05/01/23 Vertex Pharmaceuticals reports Q1 EPS $2.69, consensus $3.00 02/07/23 Vertex Pharmaceuticals guides FY23 revenue $9.55B-$9.70B, consensus $9.6B 02/07/23 Vertex Pharmaceuticals reports Q4 EPS $3.76, consensus $3.51 VRTX Vertex Pharmaceuticals $329.89 / -2.63 (-0.79%) 02/07/23 Vertex keeps cystic fibrosis drug out of developing countries, NY Times reports VRTX Vertex Pharmaceuticals $329.89 / -2.63 (-0.79%) 05/04/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/01/23 Fly Intel: After-Hours Movers 03/21/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 03/09/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations VRTX Vertex Pharmaceuticals $329.89 / -2.63 (-0.79%) 05/01/23 Vertex options imply 3.8% move in share price post-earnings 02/07/23 Vertex options imply 3.7% move in share price post-earnings
Hot Stocks	C4 Therapeutics, Betta enter exclusive licensing agreement for CFT8919 » 07:10 05/30/23 05/30 07:10 05/30/23 07:10 CCCC C4 Therapeutics $3.08 / -0.015 (-0.48%) C4 Therapeutics and Betta… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:10 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events CCCC C4 Therapeutics $3.08 / -0.015 (-0.48%) 05/04/23 C4 Therapeutics announces key upcoming milestones 02/28/23 Tango Therapeutics appoints Crystal as President of Research, Development 02/23/23 C4 Therapeutics announces upcoming milestones 01/30/23 C4 Therapeutics announces first patient dosed in Phase 1/2 trial of CFT1946 CCCC C4 Therapeutics $3.08 / -0.015 (-0.48%) 06:35 Today Evercore ISI C4 Therapeutics price target lowered to $10, transferred at Evercore ISI 05/08/23 H.C. Wainwright C4 Therapeutics price target lowered to $25 from $35 at H.C. Wainwright 03/28/23 BofA C4 Therapeutics price target lowered to $5 from $11 at BofA 02/24/23 Credit Suisse Credit Suisse ups C4 Therapeutics to Neutral on 'dramatically' improved outlook CCCC C4 Therapeutics $3.08 / -0.015 (-0.48%) 05/04/23 C4 Therapeutics reports Q1 EPS (71c), consensus (75c) 02/23/23 C4 Therapeutics reports 2022 EPS ($2.62), consensus ($2.57) CCCC C4 Therapeutics $3.08 / -0.015 (-0.48%) 02/24/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/15/23 C4 Therapeutics, Inc.
Hot Stocks	JBT Corporation to sell its AeroTech business to Oshkosh for $800M » 07:10 05/30/23 05/30 07:10 05/30/23 07:10 JBT JBT Corporation $105.75 / +3.07 (+2.99%) , OSK Oshkosh $73.89 / -0.205 (-0.28%) JBT Corporation (JBT)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:10 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly OSK OSK Oshkosh $73.89 / -0.205 (-0.28%) 05/09/23 State Department approves Oshkosh FMS sale to Slovakia for JLTVs 03/06/23 Oshkosh Defense files bid protest on recent JLTV award decision 02/10/23 Oshkosh falls -12.1% 01/31/23 Oshkosh announces 11% dividend hike to 41c per share JBT OSK JBT JBT Corporation $105.75 / +3.07 (+2.99%) 04/26/23 Baird Baird bumps JBT Corporation price target to $128 after Q1 beat 11/02/22 BMO Capital JBT Corporation price target lowered to $120 from $135 at BMO Capital 10/28/22 Baird JBT Corporation price target lowered to $110 from $117 at Baird 10/27/22 Baird JBT Corporation price target lowered to $110 from $117 at Baird OSK Oshkosh $73.89 / -0.205 (-0.28%) 05/09/23 Evercore ISI Oshkosh price target lowered to $82 from $89 at Evercore ISI 05/01/23 DA Davidson Oshkosh price target lowered to $86 from $95 at DA Davidson 04/28/23 Stifel Oshkosh price target lowered to $101 from $109 at Stifel 04/28/23 Credit Suisse Oshkosh price target lowered to $96 from $113 at Credit Suisse JBT OSK JBT JBT Corporation $105.75 / +3.07 (+2.99%) 04/25/23 JBT Corporation backs FY23 EPS view $5.00-$5.50, consensus $5.34 04/25/23 JBT Corporation sees Q2 adjusted EPS $1.10-$1.25, consensus $1.24 04/25/23 JBT Corporation reports Q1 adjusted EPS 94c, consensus 73c 02/21/23 JBT Corporation sees FY23 adjusted EPS $5.00-$5.50, consensus $5.46 OSK Oshkosh $73.89 / -0.205 (-0.28%) 04/27/23 Oshkosh reports Q1 EPS $1.59, consensus $1.02 01/31/23 Oshkosh sees FY23 EPS $5.50, consensus $6.55 01/31/23 Oshkosh reports Q4 EPS $1.60, consensus $1.73 OSK OSK Oshkosh $73.89 / -0.205 (-0.28%) 01/31/23 What You Missed On Wall Street This Morning
General news	Oil Action: » 07:10 05/30/23 05/30 07:10 05/30/23 07:10 $ECON Economic Data / + Oil Action: oil prices… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:10 Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly Technical Analysis $ECON Economic Data / + 03/22/23 Senators Scott, Warren unveil bipartisan Fed oversight legislation 03/01/23 Einhorn says investors should be 'bearish on stocks and bullish on inflation' $ECON Economic Data / + $ECON Economic Data / + 05/25/23 Biden, McCarthy edging close to debt ceiling deal, Reuters reports 03/29/23 Powell did not 'predict' another rate hike in meeting, CNBC reports 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says 03/08/23 Biden to propose 25% billionaire tax, Bloomberg says $ECON Economic Data / + 05/24/23 What You Missed On Wall Street On Wednesday 05/03/23 What You Missed On Wall Street On Wednesday 04/19/23 What You Missed On Wall Street On Wednesday 03/22/23 What You Missed On Wall Street On Wednesday $ECON Economic Data / + 03/22/23 Fed says 'additional policy firming may be appropriate'
Hot Stocks	Tilray's SweetWater Brewing launches SweetWater Spirits » 07:09 05/30/23 05/30 07:09 05/30/23 07:09 TLRY Tilray $1.86 / -0.495 (-21.02%) SweetWater Brewing… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:09 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options TLRY Tilray $1.86 / -0.495 (-21.02%) 05/26/23 Hexo announces ISS recommendation for arrangement with Tilray 05/25/23 Tilray's SweetWater Brewing announces summer release of American Lager 05/25/23 Tilray announces European market expansion in Italy 05/18/23 SweetWater Brewing introduces Colorado Orange Citrus Ale TLRY Tilray $1.86 / -0.495 (-21.02%) 04/12/23 Roth MKM Tilray price target lowered to $2.50 from $3.00 at Roth MKM 04/11/23 TD Cowen Tilray price target lowered to $5 from $9 at TD Cowen 01/10/23 MKM Partners Tilray price target lowered to $3 from $4 at MKM Partners 01/10/23 Canaccord Tilray price target lowered to $5 from $7 at Canaccord TLRY Tilray $1.86 / -0.495 (-21.02%) 04/10/23 Tilray reports Q3 EPS ($1.90) vs. 9c last year 01/09/23 Tilray reports Q2 adjusted EPS (6c) vs. (8c) last year TLRY Tilray $1.86 / -0.495 (-21.02%) 04/21/23 Booker says lawmakers to revive cannabis banking bill, Marijuana Moment says 04/10/23 Tilray to buy Hexo in deal worth about $250M, Bloomberg says 12/27/22 FDA explores regulating CBD in foods, supplements, WSJ reports 12/05/22 Defense bill with marijuana reform attached is delayed, Marijuana Moment says TLRY Tilray $1.86 / -0.495 (-21.02%) 05/26/23 What You Missed On Wall Street On Friday 05/26/23 What You Missed On Wall Street This Morning 05/11/23 Here's What You Missed in Cannabis, Psychedelics This Week 05/04/23 Here's What You Missed in Cannabis This Week TLRY Tilray $1.86 / -0.495 (-21.02%) 05/08/23 Largest borrow rate increases among liquid names 05/05/23 Unusually active option classes on open May 5th 04/28/23 Unusual call flow in option market yesterday 04/27/23 Cannabis stock implied volatilities move higher as sector climbs
Hot Stocks	Plug Power makes major strategic move into Finland's green hydrogen economy » 07:08 05/30/23 05/30 07:08 05/30/23 07:08 PLUG Plug Power $8.27 / -0.115 (-1.37%) Plug Power plans to… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:08 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options PLUG Plug Power $8.27 / -0.115 (-1.37%) 05/22/23 Plug Power lands three five megawatt electrolyzer projects 05/09/23 Plug Power down 12% at $8.20 after Q1 earnings miss, below-consensus guidance 05/01/23 Plug Power unveils new high-power stationary fuel cell system 04/04/23 Plug Power manufactured 122MW of its 1MW electrolyzer stack platform in Q1 PLUG Plug Power $8.27 / -0.115 (-1.37%) 05/22/23 Piper Sandler Plug Power price target lowered to $8 from $10 at Piper Sandler 05/11/23 Truist Plug Power price target lowered to $9 from $11 at Truist 05/11/23 Northland Plug Power price target lowered to $13 from $25 at Northland 05/10/23 RBC Capital Plug Power price target lowered to $12 from $17 at RBC Capital PLUG Plug Power $8.27 / -0.115 (-1.37%) 05/09/23 Plug Power sees FY23 revenue $1.2B-$1.4B, consensus $1.34B 05/09/23 Plug Power sees FY24 revenue $1.2B-$1.4B, consensus $2.07B 05/09/23 Plug Power reports Q1 EPS (35c), consensus (26c) 03/01/23 Plug Power sees FY23 revenue $1.4B, consensus $1.37B PLUG Plug Power $8.27 / -0.115 (-1.37%) 05/27/23 Short Report: Bears reload on Mobileye after sharp gains in stock price 05/09/23 What You Missed On Wall Street This Morning 04/24/23 What You Missed This Week in EVs and Clean Energy 04/18/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/27/23 Plug Power Inc PLUG Plug Power $8.27 / -0.115 (-1.37%) 05/22/23 Unusually active option classes on open May 22nd 05/19/23 Plug Power call volume above normal and directionally bullish 05/18/23 Plug Power call volume above normal and directionally bullish 05/17/23 Plug Power call volume above normal and directionally bullish
Hot Stocks	Resolute Forest selling Thunder Bay pulp and paper mill » 07:08 05/30/23 05/30 07:08 05/30/23 07:08 RFP Resolute Forest $21.91 / + (+0.00%) Resolute Forest has… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:08 Get Free Trial ShowHide Related Items >><< Company News Street Research Options RFP Resolute Forest $21.91 / + (+0.00%) 12/28/22 Resolute, Paper Excellence merger gets Canadian Competition Bureau approval 12/19/22 Resolute Forest exec Minguez sells 47,594 common shares RFP Resolute Forest $21.91 / + (+0.00%) 02/27/23 Scotiabank Resolute Forest downgraded to Underperform from Sector Perform at Scotiabank 10/18/22 RBC Capital Resolute Forest downgraded to Sector Perform from Outperform at RBC Capital 10/18/22 RBC Capital Resolute Forest downgraded to Sector Perform from Outperform at RBC Capital 08/09/22 TD Securities Resolute Forest downgraded to Tender from Hold at TD Securities RFP Resolute Forest $21.91 / + (+0.00%) 03/21/23 Three new option listings and option delistings on March 21st
Initiation	Crispr Therapeutics resumed with an Outperform at William Blair » 07:07 05/30/23 05/30 07:07 05/30/23 07:07 CRSP Crispr Therapeutics $64.66 / +0.8 (+1.25%) William Blair resumed… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:07 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options CRSP Crispr Therapeutics $64.66 / +0.8 (+1.25%) 04/27/23 Crispr Therapeutics CEO Kulkarni sells $1.3M in company shares 04/03/23 Vertex Pharmaceuticals, Crispr Therapeutics complete rolling BLAs to FDA 03/29/23 Crispr Therapeutics announces departure of board member 03/27/23 Vertex Pharmaceuticals, Crispr Therapeutics enter CRISPR/Cas9 licensing pact CRSP Crispr Therapeutics $64.66 / +0.8 (+1.25%) 05/23/23 Citi Crispr Therapeutics price target raised to $70 from $55 at Citi 05/09/23 Stifel Crispr Therapeutics price target lowered to $64 from $69 at Stifel 04/13/23 Cantor Fitzgerald Cantor starts Crispr Therapeutics at Overweight on commercialization chances 04/13/23 Cantor Fitzgerald Crispr Therapeutics initiated with an Overweight at Cantor Fitzgerald CRSP Crispr Therapeutics $64.66 / +0.8 (+1.25%) 05/08/23 Crispr Therapeutics reports Q1 EPS (67c), consensus ($1.70) 02/22/23 Crispr Therapeutics reports Q4 EPS ($1.41) vs. ($1.84) y/y CRSP Crispr Therapeutics $64.66 / +0.8 (+1.25%) 04/13/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/13/23 Fly Intel: Pre-market Movers 06/02/23 2023 ASCO Annual Meeting CRSP Crispr Therapeutics $64.66 / +0.8 (+1.25%) 05/26/23 Crispr Therapeutics put volume heavy and directionally bearish 05/11/23 Crispr Therapeutics put volume heavy and directionally bearish 05/09/23 Crispr Therapeutics call volume above normal and directionally bullish 05/08/23 Crispr Therapeutics options imply 4.2% move in share price post-earnings
Hot Stocks	Aurora Europe, Ethypharm chosen to supply dried medical cannabis flower » 07:07 05/30/23 05/30 07:07 05/30/23 07:07 ACB Aurora Cannabis / + Aurora Europe GmbH, a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:07 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options ACB Aurora Cannabis / + 04/27/23 Bipartisan lawmakers reintroduce Safe Banking Act for cannabis businesses 04/26/23 Aurora Cannabis partners with Strainprint for tracking program 04/17/23 Curaleaf spikes over 7% after NJ CRC Board reverses, okays adult use renewals 03/24/23 Aurora Cannabis announces Nasdaq notice of non-compliance ACB Aurora Cannabis / + 02/13/23 CIBC Aurora Cannabis price target lowered to C$1.75 from C$2.25 at CIBC 02/10/23 Canaccord Aurora Cannabis price target lowered to C$1.50 from C$2 at Canaccord 02/10/23 Canaccord Aurora Cannabis price target lowered to C$1.50 from C$2.00 at Canaccord 01/27/23 Stifel Aurora Cannabis price target lowered to C$1.45 from C$1.75 at Stifel ACB Aurora Cannabis / + 02/09/23 Aurora Cannabis reports Q2 adjusted EBITDA C$1.4M vs. (C$7.1M) a year ago 02/09/23 Aurora Cannabis reports Q2 revenue C$61.7M vs. C$60.6M a year ago ACB Aurora Cannabis / + 04/21/23 Booker says lawmakers to revive cannabis banking bill, Marijuana Moment says 12/27/22 FDA explores regulating CBD in foods, supplements, WSJ reports 12/05/22 Defense bill with marijuana reform attached is delayed, Marijuana Moment says ACB Aurora Cannabis / + 05/11/23 Here's What You Missed in Cannabis, Psychedelics This Week 05/04/23 Here's What You Missed in Cannabis This Week 04/20/23 Here's What You Missed in Cannabis This Week 04/13/23 Here's What You Missed in Cannabis This Week ACB Aurora Cannabis / + 05/24/23 Largest borrow rate increases among liquid names 05/23/23 Largest borrow rate increases among liquid names 05/22/23 Aurora Cannabis options imply 17.4% move in share price post-earnings 05/18/23 Aurora Cannabis options imply 11.0% move in share price post-earnings
Syndicate	Oculis offers to sell 5M shares of common stock » 07:07 05/30/23 05/30 07:07 05/30/23 07:07 OCS Oculis $11.62 / -0.48 (-3.97%) BofA Securities and SVB… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:07 Get Free Trial ShowHide Related Items >><< Company News Street Research On The Fly Events OCS Oculis $11.62 / -0.48 (-3.97%) 05/22/23 Oculis' OCS-01 eye drops meet efficacy endpoint in Phase 3 macular edema trial 04/26/23 Oculis opens new office in Boston, appoints Fang Li as SVP, regulatory affairs 04/04/23 Oculis to host call to discuss late-stage pipeline, near-term milestones 03/16/23 Oculis completes enrollment in Phase 3 OCS-01 OPTIMIZE trial OCS Oculis $11.62 / -0.48 (-3.97%) 05/10/23 Pareto Oculis initiated with a Buy at Pareto 04/28/23 Wedbush Oculis initiated with an Outperform at Wedbush OCS Oculis $11.62 / -0.48 (-3.97%) 04/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/02/23 Biotech/Biopharma

Hot Stocks	Atea Pharmaceuticals board rejects unsolicited proposal from Tang Capital » 07:06 05/30/23 05/30 07:06 05/30/23 07:06 AVIR Atea Pharmaceuticals $4.70 / +0.065 (+1.40%) Atea Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:06 Get Free Trial ShowHide Related Items >><< Company News Earnings Events AVIR Atea Pharmaceuticals $4.70 / +0.065 (+1.40%) 05/23/23 Atea Pharmaceuticals confirms receipt of Concentra Biosciences proposal 05/22/23 Atea Pharmaceuticals up 37% after buyout offer from Tang Capital 05/22/23 Tang Capital reports 3.6% stake in Atea Pharmaceuticals 04/25/23 Atea Pharmaceuticals announces U.S. FDA FTD granted to bemnifosbuvir AVIR Atea Pharmaceuticals $4.70 / +0.065 (+1.40%) 05/08/23 Atea Pharmaceuticals reports Q1 EPS (43c), consensus (48c) 02/28/23 Atea Pharmaceuticals reports Q4 EPS (41c), consensus (45c) 06/16/23 Atea Pharmaceuticals, Inc.
Hot Stocks	Arcimoto announces availability of new Arcimoto MUV » 07:06 05/30/23 05/30 07:06 05/30/23 07:06 FUV Arcimoto $1.54 / +0.09 (+6.21%) Arcimoto announced the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:06 Get Free Trial ShowHide Related Items >><< Company News Street Research Syndicate On The Fly Events FUV Arcimoto $1.54 / +0.09 (+6.21%) 05/09/23 Arcimoto announces strategic agreement with Faction Technology 04/20/23 Arcimoto appoints Chris Dawson as CEO 03/01/23 Arcimoto opens vehicles sales in 4 new states 02/21/23 Arcimoto to begin 2023 vehicle production for spring deliveries FUV Arcimoto $1.54 / +0.09 (+6.21%) 02/15/23 Dawson James Arcimoto upgraded to Neutral from Sell at Dawson James 12/01/22 Alliance Global Partners Arcimoto price target raised to $11 from $7 at Alliance Global Partners 09/06/22 Dawson James Arcimoto downgraded to Sell from Neutral at Dawson James 06/21/22 Dawson James Arcimoto producing more cars but still needs cash, says Dawson James 18 Jan FUV Arcimoto $1.54 / +0.09 (+6.21%) 01/17/23 Fly Intel: After-Hours Movers 06/16/23 Arcimoto, Inc.
Upgrade	Knot Offshore Partners upgraded to Buy from Neutral at Alliance Global Partners » 07:06 05/30/23 05/30 07:06 05/30/23 07:06 KNOP Knot Offshore Partners $4.81 / -0.035 (-0.72%) Alliance Global Partners… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:06 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly KNOP Knot Offshore Partners $4.81 / -0.035 (-0.72%) 04/10/23 Knot Offshore Partners CEO, CFO Gary Chapman steps down 01/12/23 Knot Offshore Partners falls -37.9% 01/12/23 Knot Offshore Partners falls -43.3% 01/12/23 Knot Offshore Partners falls -40.5% KNOP Knot Offshore Partners $4.81 / -0.035 (-0.72%) 02/01/23 Alliance Global Partners Knot Offshore Partners upgraded to Neutral from Sell at Alliance Global Partners 01/12/23 Alliance Global Partners Knot Offshore Partners downgraded to Sell from Buy at Alliance Global Partners 01/06/23 B. Riley Knot Offshore Partners price target lowered to $15 from $22 at B. Riley 12/13/22 Alliance Global Partners Knot Offshore Partners initiated with a Buy at Alliance Global Partners KNOP Knot Offshore Partners $4.81 / -0.035 (-0.72%) 05/25/23 Knot Offshore Partners reports Q1 operating income $17.7M vs. $19.6M in Q4 KNOP Knot Offshore Partners $4.81 / -0.035 (-0.72%) 01/12/23 What You Missed On Wall Street On Thursday 01/12/23 What You Missed On Wall Street This Morning
Hot Stocks	Diebold signs debt restructuring agreement with key stakeholders » 07:05 05/30/23 05/30 07:05 05/30/23 07:05 DBD Diebold / + Diebold has entered into… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:05 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Options DBD Diebold / + 05/05/23 Diebold receives continued listing standard notice from NYSE 03/21/23 Diebold confirms closing on $55M of additional liquidity 03/16/23 Diebold down 9%, sees risk to generating cash to sustain operating needs 02/06/23 Diebold announces Octavio Marquez was elected Chairman DBD Diebold / + 05/04/23 Wedbush Wedbush downgrades Diebold to Neutral, lowers price target to $1 05/04/23 Wedbush Diebold downgraded to Neutral from Outperform at Wedbush 03/17/23 Wedbush Wedbush keeps Outperform rating on Diebold after mid-quarter update 10/24/22 DA Davidson Diebold downgraded to Neutral from Buy at DA Davidson DBD Diebold / + 05/03/23 Diebold sees FY23 revenue $3.7B-$3.9B, consensus $3.82B 05/03/23 Diebold reports Q1 non-GAAP EPS (85c), consensus 7c 02/09/23 Diebold reports Q4 adjusted EPS 79c, consensus 38c DBD Diebold / + 04/11/23 Largest borrow rate increases among liquid names 04/10/23 Largest borrow rate increases among liquid names
Hot Stocks	Telesat Holdings selects SFL to manufacture LEO 3 demonstration satellite » 07:05 05/30/23 05/30 07:05 05/30/23 07:05 TSAT Telesat Holdings $6.91 / -0.34 (-4.69%) Telesat announced a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 2nd, 07:05 Get Free Trial ShowHide Related Items >><< Company News Earnings TSAT Telesat Holdings $6.91 / -0.34 (-4.69%) 02/08/23 Mynaric delivers CONDOR Mk2terminals to Telesat Government Solutions 02/07/23 Telesat selected by Anuvu to provide antennas, ground-station infrastructure 12/19/22 Telesat Holdings appoints Harlow as President of Telesat Government Solutions 12/15/22 Spacecom completes testing campaign of Telesat's LEO demonstration satellite TSAT Telesat Holdings $6.91 / -0.34 (-4.69%) 05/11/23 Telesat Holdings sees 2023 revenue C$690M-C$710M 05/11/23 Telesat Holdings reports Q1 EPS C$0.60 vs. C$1.13 last year 03/29/23 Telesat Holdings sees FY23 revenue $690M-$710M 03/29/23 Telesat Holdings reports Q4 EPS C$1.76 vs C$1.28 last year

Events

Earnings calls, analyst events, roadshows and more

GLNG
Today at 08:00

Golar LNG - GLNG Conference Calls
BNR
Today at 08:00

Burning Rock Biotech - BNR Conference Calls
TIGR
Today at 08:00

UP Fintech - TIGR Conference Calls
GOTU
Today at 08:00

Gaotu Techedu - GOTU Conference Calls
TCRR
Today at 08:00

TCR2 Therapeutics Inc. Firm Sponsored Meetings
YTRA
Today at 08:30

Yatra - YTRA Conference Calls
MDWD
Today at 08:30

MediWound - MDWD Conference Calls
Today at 09:00

Case-Shiller Home Price Index: 20-City Unadjusted Y/Y: March 2023 Government Event
Today at 09:00

FHFA House Price Index M/M: March 2023 Government Event
Today at 09:00

FHFA House Price Index Y/Y: March 2023 Government Event

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	AZTR X AZTR Azitra IPO Managers: ThinkEquity $4.50-5.50 2.4M Shares SXTP X SXTP 60 Degrees Pharmaceuticals IPO Managers: WallachBeth $4.30-6.30 1.415M Shares
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

Ionis Pharmaceuticals' IONIS-MAPTRx shows tau reduction efficacy in Alzheimer's

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access